Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mathieu Rouanne has received pre-clinical and clinical research grants (institutional funding) from AstraZeneca and Ipsen. Nicholas Arpaia discloses a financial interest in GenCirq, Inc. Aurélien Marabelle has received research grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi; has received Pre-Clinical and Clinical Research Grants (Institutional Funding) from Merus, BMS, Boehringer Ingelheim, Transgene, Fondation MSD Avenir, Sanofi; is a member of Clinical Trial Steering Committee: NCT02528357 (GSK), NCT03334617 (AZ) and Data Safety and Monitoring Board: NCT02423863 (Sponsor: Oncovir), NCT03818685 (Sponsor: Centre Léon Bérard); has participated in Scientific Advisory Boards: Merck Serono, eTheRNA, Lytix pharma, Kyowa Kirin Pharma, Novartis, BMS, Symphogen, Genmab, Amgen, Biothera, Nektar, Tesaro/GSK, Oncosec, Pfizer, Seattle Genetics, Astra Zeneca/Medimmune, Servier, Gritstone, Molecular Partners, Bayer, Partner Therapeutics, Sanofi, Pierre Fabre, RedX pharma, OSE Immunotherapeutics, Medicxi, HiFiBio, IMCheck, MSD; has received teaching/speaker activities from Roche/Genentech, BMS, Merck (MSD), Merck Serono, Astra Zeneca/Medimmune, Amgen, Sanofi, Servier; has received fees for Scientific & Medical Consulting: Roche, Pierre Fabre, Onxeo, EISAI, Bayer, Genticel, Rigontec, Daichii Sankyo, Imaxio, Sanofi/BioNTech, Molecular Partners, Pillar Partners, BPI, Faron; has received non-financial support (travel expenses) from Astra Zeneca, BMS, Merck (MSD), Roche; is co-founder and shareholder of Pegascy SAS & PEGA-1 SAS; is patent holder: patent issued (not licensed): “Humanised and Chimeric Monoclonal Antibodies to CD81”, Stanford Office of Technology Licensing, 3000 El Camino Real, Bldg. 5, Suite 300, Palo Alto, CA 94306-2100. U.S. Application Serial No. 62/351,054.